drugset / Trial / NCT00479349

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531

NCT00479349

Phase 1 Completed 32 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

To assess the safety and tolerability of ascending multiple oral doses of SAM-531, an investigational drug, in healthy Japanese young male and elderly subjects.To provide the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of multiple oral doses of SAM-531 in healthy Japanese young male and elderly subjects.

Timeline

Start
2007-05
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator CERLAPIRDINE Small molecule 1.5 mg Oral
Comparator CERLAPIRDINE Small molecule 3 mg Oral
Comparator CERLAPIRDINE Small molecule 5 mg Oral

Indications